Xenon Pharmaceuticals Inc. $XENE Shares Acquired by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its holdings in Xenon Pharmaceuticals Inc. by 42.4%, now owning 404,154 shares worth approximately $13.56 million.
• A variety of analysts have recently adjusted their price targets and ratings for the stock, with estimates ranging from a low of $47.00 to a high of $55.00 and an average rating of "Moderate Buy".
• Xenon Pharmaceuticals reported an EPS of ($1.07) for the last quarter, missing the consensus estimate of ($1.03), while its stock opened at $37.82 with a market cap of $2.92 billion.

Aberdeen Group plc boosted its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 42.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 404,154 shares of the biopharmaceutical company's stock after acquiring an additional 120,255 shares during the period. Aberdeen Group plc owned about 0.53% of Xenon Pharmaceuticals worth $13,559,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of XENE. Geode Capital Management LLC lifted its holdings in Xenon Pharmaceuticals by 1.0% in the fourth quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock worth $2,726,000 after acquiring an additional 720 shares during the last quarter. Raymond James Financial Inc. bought a new position in Xenon Pharmaceuticals in the fourth quarter worth about $797,000. Barclays PLC lifted its holdings in Xenon Pharmaceuticals by 20.9% in the fourth quarter. Barclays PLC now owns 18,127 shares of the biopharmaceutical company's stock worth $711,000 after acquiring an additional 3,134 shares during the last quarter. XTX Topco Ltd bought a new position in Xenon Pharmaceuticals in the fourth quarter worth about $316,000. Finally, J. Safra Sarasin Holding AG bought a new position in Xenon Pharmaceuticals in the fourth quarter worth about $697,000. Institutional investors own 95.45% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on XENE shares. Wells Fargo & Company cut their target price on shares of Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating on the stock in a report on Tuesday, May 13th. Wall Street Zen cut Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Wedbush lifted their price target on Xenon Pharmaceuticals from $42.00 to $43.00 and gave the company an "outperform" rating in a report on Tuesday, August 12th. Evercore ISI started coverage on Xenon Pharmaceuticals in a report on Wednesday, May 14th. They set an "outperform" rating and a $55.00 price target on the stock. Finally, Needham & Company LLC cut their price target on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. One analyst has rated the stock with a sell rating and eleven have given a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $53.20.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ:XENE opened at $37.82 on Tuesday. Xenon Pharmaceuticals Inc. has a 12 month low of $26.74 and a 12 month high of $46.00. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of -10.65 and a beta of 1.16. The stock's 50 day moving average price is $32.72 and its 200 day moving average price is $33.96.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last announced its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period in the previous year, the company earned ($0.75) earnings per share. On average, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current year.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.